bêta
IA Trial Radar
L'essai clinique NCT06539624 pour Maladie de Fabry est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Retour à la recherche

Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease 12

En recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'étude' pour voir et discuter des informations sur l'étude dans la langue sélectionnée.
L'essai clinique NCT06539624 est une étude interventionnel pour Maladie de Fabry. Son statut actuel est : en recrutement. L'étude a débuté le 16 octobre 2024 et vise à recruter 12 participants. Dirigée par The Children's Hospital of Zhejiang University School of Medicine, l'étude devrait être terminée d'ici le 9 avril 2027. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 27 février 2026.
Résumé succinct
Objective: To explore the safety and tolerability of different doses of EXG110 with Fabre disease
Description détaillée
An open-label, multicenter, single-arm, non-randomized, dose-escalation, and recommended dose-extension clinical design was used to evaluate the safety and efficacy of a single intravenous administration of different doses of EXG110 in patients
Titre officiel

A Multicenter, Non-randomized, Open-label, Dose-finding Study to Evaluate the Safety and Preliminary Efficacy of Gene Therapy With EXG110 in Subjects With Fabry Disease

Pathologies
Maladie de Fabry
Autres identifiants de l'étude
  • EXG110-011
Numéro NCT
NCT06539624
Date de début (réel)
2024-10-16
Dernière mise à jour publiée
2026-02-27
Date de fin (estimée)
2027-04-09
Inscription (estimée)
12
Type d'étude
Interventionnel
PHASE
N/A
Statut
En recrutement
Objectif principal
Traitement
Méthode d'allocation
Non randomisé
Modèle d'intervention
Séquentiel
Masquage
Aucun (ouvert)
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
ExpérimentalDose escalation-Cohort 1
Genetic : EXG110
EXG110 injection
EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.
ExpérimentalDose escalation-Cohort 2
Genetic : EXG110
EXG110 injection
EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.
ExpérimentalDose escalation-Cohort 3
Genetic : EXG110
EXG110 injection
EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.
ExpérimentalDose escalation-Cohort 4
Genetic : EXG110
EXG110 injection
EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.
Critère principal d'évaluation
Critères d'évaluationDescription de la mesurePériode
Incidence and severity of adverse events
Safety and tolerability of EXG110 following a single IV dose, as assessed by incidence and severity of adverse events, serious adverse events and dose limiting toxicities, including clinically significant changes from baseline to scheduled time points in safety parameters
52 weeks following EXG110 administration
Critère secondaire d'évaluation
Critères d'évaluationDescription de la mesurePériode
eGFR change from baseline in mL/min/(1.73m^2);
eGFR change from baseline in mL/min/(1.73m\^2)
52 weeks following EXG110 administration
NYHA cardiac function grade changed from baseline;
NYHA cardiac function grade changed from baseline;
52 weeks following EXG110 administration
Changed from baseline: region and area in mm^2 of skin angiokeratoma The number of Gb3 deposition in skin biopsy under the microscope
Changed from baseline: region and area in mm\^2 of skin angiokeratoma The number of Gb3 deposition in skin biopsy under the microscope
52 weeks following EXG110 administration
Change from baseline in serum AGA activity
Change from baseline in serum AGA activity
52 weeks following EXG110 administration
Change from baseline serum lysoGb3
Change from baseline serum lysoGb3
52 weeks following EXG110 administration
Assistant à la participation
Critères d'éligibilité

Âges éligibles
Enfant, Adulte, Adulte âgé
Âge minimum
7 Years
Sexes éligibles
Tous
  1. At the time of signing the informed consent, age ≥7, male or female
  2. Clinical symptoms (at least one Fabry disease related symptom) and genetic diagnosis of Fabry disease,
  3. Prior or no prior ERT treatment
  4. Have renal or cardiac involvement (adults only)
  5. All subjects of reproductive age voluntarily took effective contraception and prohibited sperm donation from entering the screening period until 52 weeks after dosing (main study period)
  6. The subjects voluntarily participate and are fully informed, fully understand the research, can comply with the requirements of the research protocol, and are willing to complete the research as planned, and voluntarily provide biological samples for testing according to the requirements of the protocol

  1. Screening period laboratory test results: a) aspartate aminotransferase or alanine aminotransferase > 1.5× upper limit of normal (ULN);b) Total bilirubin > 1.5× upper limit of normal (ULN);c) Alkaline phosphatase > 2× upper limit of normal (ULN);d) Albumin < lower limit of normal (LLN)
  2. There was a clinically significant increase in AFP during the screening period
  3. Serum virology test: a) Hepatitis B: Hepatitis B virus surface antigen (HBsAg) positive, and hepatitis B virus-deoxyribonucleic acid (HBV-DNA) higher than the upper limit of normal detection;b) Hepatitis C: if the hepatitis C virus (HCV) antibody is positive, and the hepatitis C virus-ribonucleic acid (HCV-RNA) is higher than the upper limit of normal test value;c) Syphilis: positive for syphilis screening (Tp-Ab) and positive for syphile-specific antibodies;d) HIV: Known human immunodeficiency virus (HIV) positive history or HIV screening positive
  4. AVT917 (>1:50), anti-AGA antibody positive(>1:2560)
  5. C3 lower than the normal range, C5b-9 higher than the normal range, anti-AVT917 IgM positive
  6. Current or have a history of serious cardiovascular disease and surgical history
  7. Current underlying liver disease or history of liver disease, as assessed by the investigator, that may affect the safety assessment of the drug
  8. Renal disease in adult and the slope of kidney >5 mL/min/1.73m²/year
  9. Subjects with poorly controlled diabetes after drug treatment (e.g., HbA1c≥8%);
  10. Acute/chronic infection or other chronic disease that the investigator determines will increase the risk of participants participating in the study
  11. Patients with a history of malignant tumor or currently suffering from any malignant tumor (except for the following tumor diseases: skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ, skin squamous cell carcinoma has been controlled after treatment);
  12. Have malignancy cancer
  13. Patients with active autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, immune vasculitis, inflammatory bowel disease, etc.);
  14. known history of allergy to the components of the investigational products
  15. Patients with a history of drug use or drug abuse or alcoholism
  16. Use of systemic (intravenous or oral) immunomodulators within the past 6 months or currently
  17. Initiation of treatment with blood pressure lowering drugs that affect proteinuria levels (such as angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or angiotensin-receptor/enkephalin inhibitors) within 4 weeks prior to screening, or changes in the therapeutic dose of these drugs within 4 weeks prior to screening;
  18. Has received, or is currently receiving, a clinical trial of another investigational drug/medical device or treatment (other than vitamins and minerals) within 3 months prior to signing the informed consent (or within 5 half-lives of the investigational drug, whichever is longer)
  19. Previous treatment with gene therapy products
  20. Those who had received live attenuated vaccine/vaccine within 12 weeks prior to screening or planned to receive it during the study
  21. Other clinical conditions that the investigators felt needed to be ruled out
The Children's Hospital of Zhejiang University School of Medicine logoThe Children's Hospital of Zhejiang University School of Medicine
Partie responsable de l'étude
Mao Jianhua, Investigateur principal, Vice President of the hospital, The Children's Hospital of Zhejiang University School of Medicine
Contact central de l'étude
Contact: Jianhua Mao, PhD, 13516819071, [email protected]
2 Centres de l'étude dans 1 pays

Shanghai Municipality

Shanghai Children's Medical Center, Shanghai, Shanghai Municipality, China
Lei Yin, PhD, Contact, 13641673203, [email protected]
Lei Yin, PhD, Investigateur principal
En recrutement

Zhejiang

Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Mao Jianhua, MD, Contact, 13616819071, [email protected]
En recrutement